PA
AMLX icon

Perceptive Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Perceptive Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,679,125
Closed -$4.77M – 113
2024
Q1 		$4.77M Buy
+1,679,125
New +$22M 0.08% 88

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Perceptive Advisors's AMLX Position: Q2 2026 in Review

Perceptive Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 0.6% in Q2 2026, buying an estimated $773K and bringing the position to 8,334,882 shares worth $150M. The position accounts for 2.25% of the portfolio, ranked #13.

Perceptive Advisors first reported a position in AMLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $225M in Q4 2022. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Perceptive Advisors held 8,334,882 shares of Amylyx Pharmaceuticals worth $150M as of Q2 2026.
  • Perceptive Advisors bought 50,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $773K.
  • Amylyx Pharmaceuticals made up 2.25% of Perceptive Advisors's portfolio in Q2 2026, its #13 holding.
  • Perceptive Advisors first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Perceptive Advisors's Amylyx Pharmaceuticals position peaked at $225M in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.